Trillium Therapeutics Inc (TRIL)

[jondoeuk]

TRILLIUM EXPANDS CLINICAL TRIAL WITH TTI-621 TO INCLUDE COMBINATION WITH PD-1 BLOCKADE http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2017/T rillium-Expands-Clinical-Trial-with-TTI-621-to-Include-Combination-with-PD- 1-Blockade/default.aspx

TORONTO, June 7, 2017 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company, today announced that based upon promising early evidence of anti-tumor activity in patients with both myeloid and lymphoid malignancies, it has further expanded its current intravenous dosing trial of TTI-621, an IgG1 SIRPaFc fusion protein targeting CD47.

Changes to the trial include:

An additional cohort of patients with Hodgkin lymphoma treated with a combination of TTI-621 and the PD-1 checkpoint inhibitor nivolumab
Two additional cohorts of patients with T- and B-cell acute lymphoblastic leukemia and small cell lung cancer treated with TTI-621 monotherapy
Cautious exploration of dose-intensification, building upon the observation of good overall tolerability associated with attenuated thrombocytopenia over successive weekly doses of TTI-621
Increasing the size of cohorts exhibiting early evidence of clinical benefit

“Having observed meaningful objective responses among multiple treatment-refractory cancer patients, we are now expanding the trial’s scope with additional focused enrollment to extend these preliminary observations and to seek promising new signals of activity—both with TTI-621 monotherapy, with rituximab, and in a novel combination with T-cell checkpoint inhibition,” said Trillium’s Chief Medical Officer, Dr. Eric Sievers. “With emerging data linking CD47 blockade with T cell activation, we are excited to pursue the combination of TTI-621 and nivolumab in an attempt to optimally engage both the innate and adaptive arms of the immune system to generate a robust and enduring anti-tumor response.”